The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.

The Echelon-3 study seemed doomed, but it just read out positively for overall survival.

Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?

New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.

BeiGene has a strong presence at this year’s AACR, which features several notable duels.

Projects from the likes of BioNTech, Transgene and Scancell will feature, but still have much to prove.

After beating Darzalex, GSK’s withdrawn anti-BCMA ADC beats Velcade in early multiple myeloma.